New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) and published in Nature ...
Learn how to manage hereditary angioedema (HAE) attacks with on-demand medications, from identifying early symptoms to ...
Follow enough wellness influencers on Instagram and you’re bound to run into someone waxing poetic about peptides—or even livestreaming their injections. This buzzy practice has been popular in ...
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
AmgenAMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or ...
Q1 2026 Management View "We had a strong first quarter and are well positioned to achieve our objectives for the year," said (Chairman & CEO Robert Bradway), reiterating that 2026 is "a springboard ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...
Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
DEAR DR. ROACH: I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put me on several statins that caused very sore joints and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results